OncoMatch/Clinical Trials/NCT06617000
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
Is NCT06617000 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SCG101 for hcc.
Treatment: SCG101 — This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Prior therapy
Must have received: standard systemic therapies
Subjects with HCC who have received standard systemic therapies
Cannot have received: cell therapy (killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy)
Prior exposure to any cell therapy such as, but not limited to killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy
Lab requirements
Liver function
child-pugh score ≤ 7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify